首页> 美国卫生研究院文献>Molecular and Clinical Oncology >Heterogeneity of excision repair cross-complementation group 1 gene expression in non-small-cell lung cancer patients
【2h】

Heterogeneity of excision repair cross-complementation group 1 gene expression in non-small-cell lung cancer patients

机译:非小细胞肺癌患者切除修复交叉互补1族基因表达的异质性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Excision repair cross-complementation group 1 (ERCC1) gene expression analysis is currently used widely in the molecular diagnosis of cancer. According to numerous studies, ERCC1 gene expression correlates with overall survival and effectiveness of chemotherapy with platinum agents. However, the degree of this correlation differs among various studies, with certain authors reporting a complete lack of such a correlation. These contradictions may be attributed to a number of factors, including the heterogeneity of the tumor tissue. In this study, we attempted to assess the degree of genetic heterogeneity exhibited by tissue samples obtained from non-small-cell lung cancer (NSCLC) through the expression of the ERCC1 gene. This study included 25 samples of tumor tissue from patients with a morphologically confirmed NSCLC diagnosis. A total of three randomized sections of each specimen were used. The ERCC1 gene expression was assessed by quantitative polymerase chain reaction (qPCR) in the TaqMan format. When planning the experiment and analysis of qPCR data, the MIQE guidelines were taken into consideration. We established that the coefficient of variation of the relative level of ERCC1 gene expression in the majority of the samples exceeded 33% (P<0.05), indicating the significant heterogeneity of the sample. We also demonstrated that the degree of heterogeneity of the tumor tissue is largely dependent on disease stage.
机译:切除修复交叉互补组1(ERCC1)基因表达分析目前被广泛用于癌症的分子诊断。根据大量研究,ERCC1基因表达与铂类药物化疗的总体生存率和有效性相关。但是,这种相关性的程度在各种研究中有所不同,某些作者报告说完全没有这种相关性。这些矛盾可能归因于许多因素,包括肿瘤组织的异质性。在这项研究中,我们试图通过ERCC1基因的表达来评估从非小细胞肺癌(NSCLC)获得的组织样本所表现出的遗传异质性程度。该研究包括25例经形态学确诊的NSCLC诊断患者的肿瘤组织样本。每个样品总共使用三个随机切片。通过TaqMan格式的定量聚合酶链反应(qPCR)评估ERCC1基因的表达。在计划实验和qPCR数据分析时,要考虑MIQE指南。我们确定大多数样品中ERCC1基因表达的相对水平的变异系数超过33%(P <0.05),表明样品具有明显的异质性。我们还证明了肿瘤组织的异质性很大程度上取决于疾病的阶段。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号